RWD124 Characteristics of Patients with Advanced Endometrial Cancer Who Received Pembrolizumab As Part of an Early Access Program (EAP) in Accordance with KN-775 Labelling
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.2841
https://www.valueinhealthjournal.com/article/S1098-3015(23)05971-5/fulltext
Title :
RWD124 Characteristics of Patients with Advanced Endometrial Cancer Who Received Pembrolizumab As Part of an Early Access Program (EAP) in Accordance with KN-775 Labelling
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)05971-5&doi=10.1016/j.jval.2023.09.2841
First page :
Section Title :
Open access? :
No
Section Order :
12168